> See all news
Valtrex regains its patent right
Valtrex regains its patent right

Published on June 9, 2014 | Category Product launch

Valtrex regains its patent right

Pharmapar wants to inform you that the pharmaceutical company Glaxo Smith Kline regained its patent right on Valtrex (Dom-Valacyclovir).

This is the reason why generics companies have stopped selling that molecule since June 1st 2014.

Therefore, it is not a stock shortage.

This new patent will expire by September 13th 2015 at the soonest, but that date still needs confirmation.

For any question or comment regarding that news, please feel free to contact your Pharmapar representative

Thank you for your trust in Pharmapar.

Partagez cette actualité par courriel

* all fields are required

Customer Service: 1-866-831-2003


Item Quantity Availability Price

Total: $0

Change my delivery address and billing
Continue shopping

Pharmacist area

Forgot your password?

Not listed yet?

Create now your account to place your order online.